



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

# Unapproved biologicals: pathways for access

Australian Regulatory Guidelines for Biologicals  
(ARGB)

Version 1.1, November 2020

**TGA** Health Safety  
Regulation

**Copyright**

© Commonwealth of Australia 20120

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to [tga.copyright@tga.gov.au](mailto:tga.copyright@tga.gov.au).

## Contents

<b>Who uses the pathways</b>	<b>4</b>
<b>Authorised prescriber scheme</b>	<b>4</b>
<b>Special access scheme</b>	<b>4</b>
<b>Clinical trials</b>	<b>5</b>
<b>Manufacture in accordance with appropriate GMP</b>	<b>5</b>

This guidance is for people who wish to access biologicals that are not included on the Australian Register of Therapeutic Goods (ARTG), and are not otherwise exempt from being in the ARTG.

Biologicals that have been entered on the ARTG have been evaluated for quality, safety and efficacy. However, if you want to access a biological that is not included on the ARTG (an 'unapproved' biological), there are several pathways, depending on whether the use is:

- as part of a clinical trial ([clinical trial schemes](#))
- for an individual patient ([special access scheme](#))
- by an individual practitioner for multiple patients ([authorised prescriber scheme](#))



You do not need to use an unapproved goods pathway if the biological is exempt from being included in the ARTG. For example, certain [autologous human cells and tissues are exempt](#).

The pathways for accessing 'unapproved' biologicals **cannot** be used to facilitate the commercial supply of therapeutic goods.

## Who uses the pathways

Most of the access pathways require a medical or dental practitioner to make the notification or a request for approval. Patients cannot make the notifications or applications themselves.

To determine which pathway, if any, is appropriate, health practitioners can use:

- [Guidance tool for access to unapproved therapeutic goods](#)

## Authorised prescriber scheme

In some circumstances a medical practitioner may be granted authority to become an authorised prescriber:

- of a specified unapproved biological
- to specific patients, or class of patients, in their immediate care with a particular medical condition.

The authorised prescriber must obtain approval from a Human Research Ethics Committee (HREC) or endorsement from a specialist college. The information will be reviewed by us to determine whether there are any safety concerns and that the requirements under the scheme have been met. You must receive an approval letter from us before supply can occur. Find out more about the [Authorised Prescriber Scheme](#).

## Special access scheme

You can use the Special Access Scheme for any regulated therapeutic good for a single patient on a case-by-case basis. Find out more about the three pathways in the [Special Access Scheme \(SAS\)](#).

## Clinical trials

There are two clinical trials schemes:

- clinical trial notification (CTN) scheme
  - clinical trial approval (CTA) scheme: an application scheme that is **mandatory** for a trial of any Class 4 biological, **unless** use of the biological in the clinical trial:
    - is supported by evidence from previous clinical use
- OR
- has been approved for an equivalent indication from a national regulatory body with comparable regulatory requirements.

Before conducting a clinical trial you need to consider whether your product is a Class 4 biological:

- check Schedule 16 [Therapeutic Goods Regulations 1990](#) to determine if you have a Class 4 biological.

For more information:

- [Choosing between CTN and CTA schemes](#)
- [Clinical trials](#)

## Manufacture in accordance with appropriate GMP

All biologicals that are accessed through unapproved goods pathways, must be manufactured in accordance with appropriate good manufacturing practice, unless there is an exemption in place. For example, there is an exemption from manufacturing in a GMP accredited facility for unapproved biologicals used in first-in-human clinical trials.

## Version history

<b>Version</b>	<b>Description of change</b>	<b>Author</b>	<b>Effective date</b>
V1.0	Original publication incorporating new legislative changes and information previously published on the TGA website.	Biological Science Section Regulatory Guidance Team	July 2018
V1.1	Minor updates to reflect CTA name change	Biological Science Section	November 2020

## **Therapeutic Goods Administration**

PO Box 100 Woden ACT 2606 Australia  
Email: [info@tga.gov.au](mailto:info@tga.gov.au) Phone: 1800 020 653 Fax: 02 6203 1605  
<https://www.tga.gov.au>

Reference/Publication #D18-10030935